Healthcare-focused private equity fund Quadria Capital will sell its entire 20% stake in active pharmaceutical ingredients (API) maker Concord Biotech in the company’s initial public offering (IPO). Rare Enterprises...
EU antitrust regulators likely to block Illumina, Grail deal – sources
EU antitrust regulators are expected to veto U.S. life sciences firm Illumina’s acquisition of biotechnology company Grail, people familiar with the matter said. There are doubts whether concessions offered by...
AstraZeneca to buy biotech firm TeneoTwo for up to $1.27 billion
AstraZeneca agreed to acquire biotechnology firm TeneoTwo Inc in a deal worth up to $1.27 billion, in a move to bolster its roster of therapies to treat blood cancers. At the heart of the deal is the U.S.-based...
Bankruptcy court temporarily stays auction of Gujarat-based Sterling Biotech
The Mumbai bench of the National Company Law Tribunal (NCLT) has directed the liquidator of Sterling Biotech to stay the auctioning process of the company until further orders. The NCLT was hearing a petition filed by...
Rossari to acquire Tristar Intermediates at enterprise value of Rs 120 cr
Rossari Biotech Ltd, a speciality chemicals manufacturer, on Sunday announced the acquisition of Tristar Intermediates at an enterprise value of Rs 120 crore. The board of the company has approved the acquisition of...
Biocon to acquire 26% stake in Hinduja Renewables Two
Biotechnology major Biocon on Monday said it has inked an agreement for the acquisition of 26 per cent stake on a fully diluted basis in Hinduja Renewables Two Pvt Ltd for Rs 5.91 crore. The indicative time period for...
Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion
Bayer agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses. Germany’s Bayer will pay $2 billion upfront and up...
Rossari Biotech raises ₹148.8 crore from anchor investors ahead of IPO
Speciality chemicals manufacturer, Rossari Biotech Ltd on Friday said that it has raised Rs148.87 crore from anchor investors, ahead of its IPO that opens on 13 July. Institutional investors that participated in the...
Japan’s AGC weighs options after Italy puts conditions on Molmed deal
Italy said it would use its right to intervene to protect strategic assets on the planned acquisition of biotechnology group Molmed by AGC, leaving the Japanese buyer to review whether to go ahead with its offer. After...
Novozymes buys Irish probiotic maker PrecisionBiotics
Danish enzyme maker Novozymes NZYMB.CO will buy Ireland-based PrecisionBiotics in a $90 million deal, it said on Thursday, its second acquisition of a probiotics company in recent years as it seeks to grow its human...
Japan’s AGC launches bid for Italian biotech firm Molmed
Japan’s AGC has launched a takeover bid on the whole of Italian biotech company Molmed in a deal worth up to 240 million euros ($267 million), AGC said on Tuesday. In its bid document, the Japanese conglomerate said it...
Asia Healthcare in talks to buy Cloudnine stake
TPG Growth-backed Asia Healthcare Holdings (AHH) has held early discussions to acquire a significant stake in maternity and childcare hospital chain Cloudnine, multiple people in the know of the development told ET. A...
